Song, Angela http://orcid.org/0009-0002-0774-4419
Zhao, Nicole
Hilpert, Diana C.
Perry, Caroline http://orcid.org/0000-0002-6022-5741
Baur, Joseph A.
Wallace, Douglas C. http://orcid.org/0000-0002-7480-8278
Schaefer, Patrick M. http://orcid.org/0000-0001-6814-3647
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NS021328, MH108592, OD010944)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Defense (W81XWH-16-1-0401, W81XWH-21-1-0128 (PR202887.e002))
Deutsche Forschungsgemeinschaft (SCHA 2182/1-1)
Article History
Received: 28 February 2023
Accepted: 29 March 2024
First Online: 9 April 2024
Competing interests
: The authors declare the following competing interests: J.A.B. is consultant to Pfizer and Cytokinetics, an inventor on a patent for using NAD+ precursors in liver injury and has received research funding and materials from Elysium Health and Metro International Biotech, both of which have an interest in NAD+ precursors. D.C.W. is part of the scientific advisory boards for Pano Therapeutics and Medical Excellence Capital. All other authors declare no competing interests.